Immunohistochemical markers for histopathological diagnosis and differentiation of acute cutaneous graft-versus-host disease
- PMID: 34223669
- DOI: 10.1111/exd.14416
Immunohistochemical markers for histopathological diagnosis and differentiation of acute cutaneous graft-versus-host disease
Abstract
Graft-versus-host disease (GvHD) is a major complication following stem-cell or solid-organ transplantation. Accurate diagnosis of cutaneous GvHD is challenging, given that drug eruptions and viral rashes may present with similar clinical/histological manifestations. Specific markers are not available. We performed the histological examination of biopsy samples from acute GvHD (aGvHD; n = 54), Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN; n = 27), maculopapular drug eruption (MDE; n = 26) and healthy controls (n = 26). Samples of aGvHD showed a decrease in Langerhans cells (LC, p = 0.0001) and an increase in macrophages (MΦ, p = 0.0001) compared to healthy skin. Compared to SJS/TEN, MDE and healthy skin, aGvHD biopsies contained greater numbers of CD4+ and CD8+ T cells. The majority of CD4+ T-helper cells were localized in the upper dermis, whereas cytotoxic CD8+ T cells were found in the epidermis. Increased numbers of CD56+ natural killer (NK) cells in the upper dermis of aGvHD skin (p = 0.007) were not observed in controls or SJS/TEN and MDE. There were no differences in elafin staining between aGvHD and the latter two conditions. Acute GvHD appears to have a distinct inflammatory cell profile (T cells/NK cells) that may aid establishing in a more accurate diagnosis, especially when used to rule out differential diagnoses such as SJS/TEN or MDE.
Keywords: Stevens-Johnson syndrome/toxic epidermal necrolysis; biomarker; graft-versus-host disease; immunohistochemistry; maculopapular drug eruption.
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Similar articles
-
Acute graft-versus-host disease presenting as Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective cohort study.J Am Acad Dermatol. 2023 Apr;88(4):792-801. doi: 10.1016/j.jaad.2022.10.035. Epub 2022 Oct 22. J Am Acad Dermatol. 2023. PMID: 36280000
-
A new nucleic acid-based agent inhibits cytotoxic T lymphocyte-mediated immune disorders.J Allergy Clin Immunol. 2013 Sep;132(3):713-722.e11. doi: 10.1016/j.jaci.2013.04.036. Epub 2013 Jun 19. J Allergy Clin Immunol. 2013. PMID: 23791505
-
Systemic and skin-limited delayed-type drug hypersensitivity reactions associate with distinct resident and recruited T cell subsets.J Clin Invest. 2024 Jul 23;134(17):e178253. doi: 10.1172/JCI178253. J Clin Invest. 2024. PMID: 39042477 Free PMC article.
-
[Dermatological conditions requiring intensive care treatment].Med Klin Intensivmed Notfmed. 2025 Mar;120(2):170-182. doi: 10.1007/s00063-024-01239-4. Epub 2025 Feb 13. Med Klin Intensivmed Notfmed. 2025. PMID: 39948146 Review. German.
-
Toxic epidermal necrolysis-like acute graft-versus-host disease in pediatric bone marrow transplant patients: Case series and review of the literature.Pediatr Dermatol. 2022 Nov;39(6):889-895. doi: 10.1111/pde.15069. Epub 2022 Jun 21. Pediatr Dermatol. 2022. PMID: 35730149 Review.
Cited by
-
A unique immune signature in blood separates therapy-refractory from therapy-responsive acute graft-versus-host disease.Blood. 2023 Mar 16;141(11):1277-1292. doi: 10.1182/blood.2022015734. Blood. 2023. PMID: 36044666 Free PMC article.
References
REFERENCES
-
- Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009;373:1550-1561.
-
- Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945-956.
-
- Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood. 1990;76:1464-1472.
-
- Hymes SR, Alousi AM, Cowen EW. Graft-versus-host disease: part I. Pathogenesis and clinical manifestations of graft-versus-host disease. J Am Acad Dermatol. 2012;66(4):515.e511-515.e518; quiz 533-514.
-
- MacDonald KP, Shlomchik WD, Reddy P. Biology of graft-versus-host responses: recent insights. Biol Blood Marrow Transplant. 2013;19:S10-S14.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials